Ardelyx Inc.
34175 Ardenwood Boulevard
Suite 100
Fremont
California
94555
United States
Tel: 510-745-1700
Website: http://www.ardelyx.com/
190 articles with Ardelyx Inc.
-
Ardelyx To Present At The 2015 JMP Securities Life Sciences Conference
6/17/2015
-
Bay Area's Ardelyx Will Go It Alone on GI Drug As it Splits With AstraZeneca PLC
6/4/2015
-
Ardelyx Inc. Presents Positive Results From Its Phase 2b Clinical Trial Evaluating Tenapanor In IBS-C Patients At Digestive Disease Week 2015
5/20/2015
-
Ardelyx Inc. Reports First Quarter 2015 Financial Results
5/13/2015
-
Ardelyx Inc. Reports Results From Phase 2a Clinical Trial Evaluating Tenapanor In Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus And Albuminuria
5/6/2015
-
Ardelyx Inc. Appoints Dr. Annalisa Jenkins To Its Board Of Directors
4/20/2015
-
Ardelyx Inc. To Present At The 22nd Annual Future Leaders In The Biotech Industry Conference
3/13/2015
-
Ardelyx Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
2/26/2015
-
Ardelyx Inc. To Report Fourth Quarter And Full Year 2014 Financial Results On February 25th, 2015
2/18/2015
-
Ardelyx Inc. To Present At The 2015 Leerink Global Healthcare Conference
2/9/2015
-
Ardelyx Inc. Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor In Treating Hyperphosphatemia In Chronic Kidney Disease Patients On Hemodialysis
2/2/2015
-
Ardelyx Inc. Appoints Jeremy S. Caldwell, Ph.D., As Executive Vice President And Chief Scientific Officer
12/1/2014
-
Ardelyx Inc.'s Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease
11/17/2014
-
Ardelyx Inc. Reports Third Quarter 2014 Financial Results
11/6/2014
-
Ardelyx Inc. To Report Third Quarter 2014 Financial Results On November 6, 2014
10/30/2014
-
Ardelyx Inc.'s Tenapanor Selected For Oral And Poster Presentations At The American Society of Nephrology's Kidney Week 2014
10/23/2014
-
Ardelyx Inc. Looks Good After Tenanpanor Results: Citi Analysts
10/1/2014
-
Ardelyx Inc. Irritable Bowel Syndrome Drug Succeeds In Phase 2b Trial
10/1/2014
-
Ardelyx Inc. Chief Scientific Officer, Dominique Charmot, Announces Retirement From The Company At Year-End
9/5/2014
-
Ardelyx Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference
8/5/2014